Aim: α-Synuclein (αSyn) is known as a small soluble protein abundantly expressed in neuronal cells. Although its physiological role is still unclear, the aggregation of αSyn has been recognized as responsible for some neurodegenerative disorders such as dementia with Lewy bodies (DLB). In most cases, intracellular abnormal aggregates are caused by protein-coding mutations that alter primary structure and therefore increase propensity toward aggregation. However, no pathogenic alterations or polymorphisms in αSyn are found in DLB patients so far, suggesting genetic mutations may not play a major role in DLB pathogenesis. In contrast, emerging evidence reveals that amyloid β (Aβ) may contribute to aggregate formation and exacerbate neurotoxicity of αSyn. However, the underlying mechanism of action has remained unclear.
| INTRODUCTION
Dementia with Lewy bodies (DLB) is a form of progressive dementia caused by degeneration of the neurons in the brain. Among adults aged 65 and over, it is widely considered as the common cause of dementia after Alzheimer's disease (AD) and vascular dementia. 1 Clinically, the central features of DLB are composed by progressive decline in both motor and cognitive function, that share symptoms sometimes overlaps with AD or Parkinson's diseases (PD). 2 At the molecular level, evidence has confirmed that α-synuclein (αSyn), a small (14.4 kDa)
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protein abundantly expressed in neuronal cells, plays a critical role in the pathogenesis of synucleinopathies such as DLB and PD. 3 Although the exact function of αSyn is not fully known, it is apparently essential for regulation of some neuronal function like synaptic plasticity and development. 4 However, αSyn can also be triggered to generate some cytoplasmic aggregates named as Lewy bodies that are strongly associated with DLB and PD pathology. Actually, aggregated αSyn inclusions are found where neuron death occurs, indicating the aggregation is the main pathogenic cause of αSyn toxicity. 5 Moreover, αSyn aggregates have been demonstrated to alter mitochondrial function and concomitant reactive oxygen species (ROS) intracellular accumulation, 6 suggesting oxidative damage may also have an important pathogenic role in DLB. 7 In most cases of neurodegenerative disorders, abnormal aggregates are generally favored by protein-coding mutations that cause conformational changes and result in formation of the misfolded proteins. Although mutations in αSyn can account for a only small fraction of PD cases, no pathogenic alterations or polymorphisms in the SNCA gene (encoding αSyn) are found in DLB. 8 In addition, overexpression of wild-type αSyn has been demonstrated nontoxic to human neuronal cells, demonstrating that protein mutations do not play a major role in DLB.
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Past studies indicate that an overlap of pathologies is found in most individuals with DLB in more than half of AD cases. 10 Similarly, the AD risk fact apolipoprotein E (ApoE) ε4 allele has also been recognized as the strongest genetic risk factor for DLB. 11 These findings further delineate the pathophysiologic connection between AD and DLB.
Furthermore, although the accumulation of amyloid β (Aβ) peptides in the brain is well-known to play a driving mechanism of AD pathogenesis, Aβ plaques are also frequently present in DLB and linked to disease severity. 12 In particular, Aβ (particularly Aβ ) was shown to effectively promote wild-type αSyn oligomerization in vitro, 13 and some studies reported Aβ may also enhance αSyn aggregation and accelerate cognitive decline in animals. 14 
| MATERIALS AND METHODS

| Materials
| Vector construction and transfection
For αSyn overexpression studies, we used a GeneSwitch System 
| Western blot analysis
| Flow cytometric analysis
At the end of the experiments, cells were harvested by trypsinization.
After centrifugation and washed twice, resuspended the cell pellet in PBS and fixed in 70% chilled ethanol. Cells were stained with propidium iodine (PI), and subsequently analyzed for DNA content using a NovoCyte flow cytometer (NovoCyte 2000, ACEA Biosciences, San
Diego, CA, USA), and data analysis was performed by NovoExpress
Software. The number of apoptotic cells was quantified by measuring the sub-G1 population.
| Immunocytochemistry and acridine orange staining
After treatment, cells were fixed with 2% buffered paraformaldehyde, permeabilized in 0.25% Triton X-100 (Sigma-Aldrich) for 5 minutes at 4°C, and then incubated with anti-αSyn primary antibody. The slides were then incubated with an FITC labeled second antibody (Santa Cruz) depending on the origin of the primary antibody. For acridine orange staining, cells were stained with 1 μg/mL acridine orange for 15 minutes and then washed with MEM medium. Then, images were taken using the fluorescence microscope (DP80/BX53, Olympus) and cellSense, V 1.9 digital imaging software.
| Microscopic observation and nucleus morphology
Changes in cell nucleus morphology, characteristic of apoptosis, were 
| Analysis of mitochondrial membrane potential
The vital mitochondrial cationic dye JC-1 was used as a tool for investigating mitochondrial function which exhibits potential-dependent accumulation in mitochondria. At normal cells, JC-1 continues to exist as a monomer and produces a red fluorescence. During the induction of Aβ cytotoxicity, the mitochondrial transmembrane potential collapse and JC-1 forms aggregates which produces a red fluorescence.
After treatment for indicated conditions, cells were treated in fresh media containing 1 μmol/L JC-1 and incubated at 37°C for 30 minutes in an incubator. After that staining medium was discarded, washed, and then the cell imaging was performed using an inverted fluorescence microscope (DP72/CKX41, Olympus).
| Statistical analysis
All data are presented as means ± standard error of the means (SEM).
Statistical analysis of data was performed using analysis of variance (ANOVA), followed by Dunnett's post hoc test for multiple comparisons with SPSS statistical software (SPSS, Inc., Chicago, IL, USA). Differences were considered statistically significant at *P < 0.05 and **P < 0.01.
| RESULTS
| Establishing an inducible in vitro model for αSyn overexpression in SK-N-MC neuronal cells
To generate a reliable conditional gene expression in vitro model, we first used the GeneSwitch System to establish an inducible expression system for αSyn overexpression in SK-N-MC neuronal cells.
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As shown in Figure 1A , the GeneSwitch system is based on the F I G U R E 2 Treatment of Aβ exacerbates αSyn-mediated neuronal apoptosis. A, MFP-induced αSyn-overexpressed cells showed no morphological evidence of cytotoxicity or apoptosis compared to control cells. However, 2.5 μmol/L Aβ markedly induced cell death, and further exacerbated cytotoxicity in αSyn-overexpressed cells. B, MTT assays indicated Aβ induces cell death by 48% after 48-h incubation, and αSyn overexpression exacerbated Aβ-stimulated cytotoxicity up to 74% of cell death. C, Flow cytometry data analysis using propidium iodide DNA staining demonstrated that Aβ significantly increased the sub-G1fraction of αSyn-overexpressed cells compared to noninduction groups. D, Western blot results showed that Aβ enhances caspase 3 and PARP cleavages in αSyn-overexpressed cells. All data were performed in three independent experiments, and values are presented as mean ± SEM. Significant difference is determined using the multiple comparisons of Dunnett's post hoc test for *P < 0.05 and **P < 0.01. N. S., no significant difference. Scale bar represents 100 μm
| Aβ exacerbates αSyn intracellular deposits and suppresses AMPK signaling in αSyn-overexpressed cells
It is generally accepted that the formation of αSyn intracellular aggregates is the major pathological hallmark of DLB. To investigate whether exogenous Aβ treatment stimulates αSyn aggregate formation in αSyn-overexpressed cells, we performed fluorescent immunostaining with a specific antibody against αSyn. As shown in Figure 3A , without Aβ treatment, no aggregates were observed in cells regardless of αSyn expression levels. On the contrary, only very few aggregates were observed in cells overexpressing αSyn only, but these aggregates were F I G U R E 3 Aβ activates mTOR by inhibiting AMPK and increases αSyn aggregates in αSyn-overexpressed cells. A, Fluorescent immunostaining images demonstrated that few αSyn aggregates were observed in αSyn-overexpressed only cells. However, these aggregates were markedly increased by co-treating with Aβ for 24 h. B, Western blots showed the protein levels of some autophagy-associated markers including LC3-II, Atg7, and Atg12-Atg5 conjugate. Aβ treatment obviously inhibited the expression of these autophagy-related proteins suggesting reduced autophagy in these cells. C, Effects of Aβ on the protein levels of p-AMPK and p-mTOR. The result showed that Aβ increases Altogether, our data demonstrated Aβ-suppressed AMPK signaling may cause upregulation of mTOR activity, which leads to reduced clearance of αSyn aggregates in αSyn-overexpressed cells.
| Reduced neuronal insulin signaling activity is observed in αSyn-overexpressed neuronal cells cotreated with Aβ
Our previous research has shown that Aβ can trigger neuronal insulin resistance, which may be functionally linked to the neurodegenerative processes. 21 To determine whether the Aβ-enhanced αSyn neurotoxicity is associated with impaired neuronal insulin signaling, we performed Western blotting to detect the level of IRS-1 phosphorylation in Ser
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, a typical marker indicates the severity of insulin resistance.
As shown in Figure 4A , the serine-phosphorylated IRS-1 exhibited These results were also confirmed by DAPI staining that treatment with insulin significantly reduced nuclei fragmentation as shown in Figure 4C , indicating Aβ-caused apoptotic events were attenuated by co-treatment of insulin in αSyn-overexpressed cells. were effectively restored by insulin treatment. Finally, we performed JC-1 staining to assess the mitochondrial membrane potential to further examine the details of insulin-mediated neuroprotection. As shown in Figure 5D , exposure of αSyn-overexpressed cells to Aβ resulted in an increase in green fluorescence, indicating a great loss of mitochondrial membrane potential. However, co-treatment with insulin reduced the effects of Aβ on mitochondrial membrane potential significantly, suggesting that insulin preserves mitochondrial function against Aβ-induced αSyn toxicity. Taken together, these results showed that Aβ-enhanced αSyn neurotoxicity can be related to impaired neuronal insulin signaling which appears to be a deleterious factor leading to increased propensity of αSyn aggregation.
| Insulin alleviates
| DISCUSSION
At present, there is still no cure for DLB, but symptoms sometimes can be alleviated with medications used for either AD or PD, indicating these diseases may have some shared pathogenic mechanisms. Although the common mechanism underlying these neurodegenerations is not fully understood, some factors have been associated with a higher risk of developing dementia. Particularly, impaired insulin signaling is associated with decreased cognitive ability and the development of dementia. 23 It is conceivable that AD can be mediated by defective insulin signaling in the brain. 24 In fact, the proximal cause of brain insulin resistance appears to be the deposition of Aβ. 25 Similarly, our recent finding also indicated that Aβ can directly cause insulin signaling blockade in neuronal cells and thus contributed to the enhanced oxidative stress leading to neuronal damage. 26 All these findings indicate that Aβ may play a central role in inhibition of insulin signaling in αSyn-overexpressed cells.
Interestingly, a previous study indicates that the presence of insulin resistance in patients with type 2 diabetes displays approximately a 40% increased risk of developing PD. 27 In addition, insulin resistance has been recognized to be associated with increased risk and more severe symptoms of PD dementia. 28 This raises the possibility that
Aβ-caused insulin resistance may enhance the development of αSyn aggregation and its neurotoxicity, which has been recognized as a key mechanism involved in PD and DLB pathogenesis. 29 Given these growing links between insulin resistance and αSyn pathology, it is not surprising that Aβ may exacerbate αSyn toxicity by disrupting neuronal insulin signaling in αSyn-overexpressed cells and therefore suggests that the insulin signaling pathway may be a novel therapeutic target for disease treatment. -IRS-1, and this increase was further upregulated by overexpression of αSyn. B, MTT assay revealed that without insulin Aβ significantly enhanced αSyn-induced cell death; however, this cell death was attenuated by exogenous supplement of insulin in a dose-dependent manner. C, DAPI staining yielded similar results, thereby indicating that treatment with insulin significantly reduced Aβ-induced nuclei fragmentation in αSyn-overexpressed cells. All data were performed in three independent experiments, and values are presented as mean ± SEM. Significant difference is determined using the multiple comparisons of Dunnett's post hoc test for *P < 0.05 and **P < 0.01. Scale bar represents 20 μm Our results also demonstrated that Aβ may suppress Nrf2/HO-1 endogenous antioxidant pathways via inhibition of insulin signaling.
Actually, Nrf2 has been found to mediate the expression of a number of antioxidant genes, suggesting increased Nrf2 signaling may be able to suppress oxidative stress in brain tissues. 30 Notably, an insulinsensitizing agent metformin which likely acts directly through activation of AMPK was reported displaying their neuroprotective potential by increasing the level of Nrf2 and HO-1 in the brain. 31 In parallel with this finding, our previous study also demonstrated that restoration of Aβ-induced neuronal insulin resistance can increase Nrf2/HO-1 signaling and subsequently elevate antioxidant enzyme expression. 26 All these supported that attenuated AMPK activation and impaired insulin signaling may act as a detecting factor representing an underlying mechanism of αSyn pathology. On the other hand, evidence suggesting that oxidative stress elicited by mitochondrial dysfunction may be involved in the process of αSyn-induced neurotoxicity. 32 Particularly, in vitro studies have shown that increasing levels of oxidative stress can lead to αSyn aggregation. 33 In fact, oxidative stress-induced posttranslational modifications have been demonstrated to play a major role in αSyn oligomerization and toxicity. 34 Moreover, ROS generated by dysfunctional mitochondria appears to accelerate αSyn phosphorylation at Ser 129 , 35 which has been identified as a pathological prognostic marker for synucleinopathy. 36 Based on these findings, we conclude that Aβ-suppressed insulin signaling may cause inhibition of Nrf2/HO-1 and result in oxidative damage to αSyn, which modulates post-translational modifications and finally affect protein aggregation.
However, the precise mechanism of action for αSyn aggregation remains to be fully elucidated. Recently, Bassil et al reported that the use of glucagon-like peptide-1 analogue exendin-4, an antidiabetic drug improving insulin sensitivity and action, has positive effects on αSyn pathologies of a multiple system atrophy animal model. 37 In accordance with our results, this indicates the restoration of neuronal insulin sensitivity can be a potential therapeutic target for treatment of these Lewy body diseases. These imply that antidiabetic drug acts against insulin resistance may provide some symptom relief for neurodegenerative synucleinopathy including DLB, as there are no effective treatments for these diseases. To our knowledge, this is the first study to shed light on the role and molecular mechanism of insulin signaling on αSyn neurotoxicity. In summary, the current study demonstrated that overexpression of αSyn alone shows nontoxic to SK-N-MC human neuronal cells.
However, co-treatment of Aβ in αSyn-overexpressed cells significantly increased αSyn intracellular aggregation and neurotoxicity. Our results also raised the possibility that Aβ-induced neuronal insulin resistance could indeed be one of the causative factors of αSyn aggregation, due to suppressed Nrf2/HO-1 antioxidative signaling and mitochondrial dysfunction. However, whether the use of insulin-sensitizing agents for treatment or prevention of αSyn-related neurodegeneration requires further investigation.
